The first real-world analysis of the Pfizer coronavirus vaccine suggests it is matching its performance in clinical trials, but raises serious questions about the UK’s decision to delay the second dose.
The first real-world analysis of the Pfizer coronavirus vaccine suggests it is matching its performance in clinical trials, but raises serious questions about the UK’s decision to delay the second dose.